Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Cell-based models to study hepatic drug metabolism and enzyme induction in humans
- M. Vermeir, P. Annaert, R. Mamidi, D. Roymans, W. Meuldermans, G. Mannens
- Biology, Medicine
- Expert opinion on drug metabolism & toxicology
- 1 June 2005
Cell-based in vitro models are invaluable tools in elucidating the pharmacokinetic profile of a drug candidate during its drug discovery and development process. As biotransformation is one of the… Expand
Metabolism and Excretion of Canagliflozin in Mice, Rats, Dogs, and Humans
- R. Mamidi, F. Cuyckens, +10 authors Heng Keang Lim
- Chemistry, Medicine
- Drug Metabolism and Disposition
- 1 May 2014
Canagliflozin is an oral antihyperglycemic agent used for the treatment of type 2 diabetes mellitus. It blocks the reabsorption of glucose in the proximal renal tubule by inhibiting the… Expand
Synthesis and biological activity of novel pyrimidinone containing thiazolidinedione derivatives.
- G. R. Madhavan, R. Chakrabarti, +8 authors R. Rajagopalan
- Chemistry, Medicine
- Bioorganic & medicinal chemistry
- 1 August 2002
A series of pyrimidinone derivatives of thiazolidinediones were synthesized. Their biological activity were evaluated in insulin resistant, hyperglycemic and obese db/db mice. In vitro PPARgamma… Expand
LC-ESI-MS/MS quantification of 4β-hydroxycholesterol and cholesterol in plasma samples of limited volume.
- Y. Xu, Y. Yuan, +6 authors Heng-Keang Lim
- Chemistry, Medicine
- Journal of pharmaceutical and biomedical analysis
- 1 November 2013
A liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) assay was developed and qualified for analyzing 4β-hydroxycholesterol and cholesterol in 5 μl of human and… Expand
In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT…
- S. Francke, R. Mamidi, +4 authors D. Devineni
- Chemistry, Medicine
- Journal of clinical pharmacology
- 1 September 2015
O‐glucuronidation is the major metabolic elimination pathway for canagliflozin. The objective was to identify enzymes and tissues involved in the formation of 2 major glucuronidated metabolites (M7… Expand
De-risking bio-therapeutics for possible drug interactions using cryopreserved human hepatocytes.
- S. Dallas, C. Sensenhauser, +8 authors J. Silva
- Biology, Medicine
- Current drug metabolism
- 31 August 2012
Inflammatory diseases such as rheumatoid arthritis and psoriasis are characterized by increases in circulating cytokines, which play an important role in modulation of the disease state. Several… Expand
Simple method for the determination of rosiglitazone in human plasma using a commercially available internal standard.
- R. Mamidi, B. Benjamin, M. Ramesh, N. Srinivas
- Chemistry, Medicine
- Biomedical chromatography : BMC
- 1 September 2003
To the best of our knowledge, bioanalytical methods to determine rosiglitazone in human plasma reported in literature use internal standards that are not commercially available. Our purpose was to… Expand
Novel euglycemic and hypolipidemic agents. 1.
- B. Lohray, V. Bhushan, +12 authors S. Subramaniam
- Medicine, Chemistry
- Journal of medicinal chemistry
- 15 April 1998
A series of [[(heterocyclyl)ethoxy]benzyl]-2,4-thiazolidinediones have been synthesized by the condensation of corresponding aldehyde 1 and 2,4-thiazolidinedione followed by hydrogenation. Both… Expand
HPLC method for the determination of rosiglitazone in human plasma and its application in a clinical pharmacokinetic study.
- R. Mamidi, M. Chaluvadi, +6 authors R. Rajagopalan
- Chemistry, Medicine
- Arzneimittel-Forschung
- 26 December 2011
Rosiglitazone (CAS 155141-29-0, Avandia) is a novel insulin sensitizer used in the treatment of type 2 diabetes. A sensitive high performance liquid chromatography (HPLC) method for its determination… Expand
Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic…
PurposeTo examine whether a conventional bioequivalence approach is sufficient to ensure the therapeutic equivalence of liposomal products, the pharmacokinetics, efficacy and toxicity of different… Expand
...
1
2
3
4
5
...